期刊
NATURE
卷 600, 期 7889, 页码 500-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41586-021-04177-9
关键词
-
资金
- European Union's Seventh Framework Program [HEALTH-F4-2012-305312]
- EMBL
- Metagenopolis grant [ANR-11-DPBS-0001]
- H2020 European Research Council [ERC-AdG-669830]
- Deutsche Forschungsgemeinschaft [SFB1365, SFB1052/3 A1, 209933838]
- NIHR Imperial Biomedical Research Centre
- French National Research Agency [ANR-10-LABX-46]
- National Center for Precision Diabetic Medicine -PreciDIAB - French National Agency for Research [ANR-18-IBHU-0001]
- European Union (FEDER)
- Hauts-de-France Regional Council [20001891/NP0025517, 20002845]
- European Metropolis of Lille (MEL) [2019_ESR_11]
- Isite ULNE [R-002-20-TALENT-DUMAS]
- ANR [ANR16-IDEX-0004-ULNE]
- European Metropolis of Lille (MEL)
The study reveals that drugs have a greater explanatory power for variability in host and gut microbiome features than diseases during the transition from a healthy state to cardiometabolic disease. The effects of single medications, their combinations, and additive effects can shift the metabolome and microbiome towards a healthier state. The study also shows a quantitative relationship between the number of antibiotic courses prescribed and progression towards a microbiome state associated with the severity of cardiometabolic disease, providing new hypotheses for drug-host-microbiome interactions.
During the transition from a healthy state to cardiometabolic disease, patients become heavily medicated, which leads to an increasingly aberrant gut microbiome and serum metabolome, and complicates biomarker discovery(1-5). Here, through integrated multi-omics analyses of 2,173 European residents from the MetaCardis cohort, we show that the explanatory power of drugs for the variability in both host and gut microbiome features exceeds that of disease. We quantify inferred effects of single medications, their combinations as well as additive effects, and show that the latter shift the metabolome and microbiome towards a healthier state, exemplified in synergistic reduction in serum atherogenic lipoproteins by statins combined with aspirin, or enrichment of intestinal Roseburia by diuretic agents combined with beta-blockers. Several antibiotics exhibit a quantitative relationship between the number of courses prescribed and progression towards a microbiome state that is associated with the severity of cardiometabolic disease. We also report a relationship between cardiometabolic drug dosage, improvement in clinical markers and microbiome composition, supporting direct drug effects. Taken together, our computational framework and resulting resources enable the disentanglement of the effects of drugs and disease on host and microbiome features in multimedicated individuals. Furthermore, the robust signatures identified using our framework provide new hypotheses for drug-host-microbiome interactions in cardiometabolic disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据